JP2022521840A5 - - Google Patents

Info

Publication number
JP2022521840A5
JP2022521840A5 JP2021558810A JP2021558810A JP2022521840A5 JP 2022521840 A5 JP2022521840 A5 JP 2022521840A5 JP 2021558810 A JP2021558810 A JP 2021558810A JP 2021558810 A JP2021558810 A JP 2021558810A JP 2022521840 A5 JP2022521840 A5 JP 2022521840A5
Authority
JP
Japan
Prior art keywords
formulation
surfactant
cholate
less
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021558810A
Other languages
English (en)
Japanese (ja)
Other versions
JP7589168B2 (ja
JP2022521840A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025683 external-priority patent/WO2020205716A1/en
Publication of JP2022521840A publication Critical patent/JP2022521840A/ja
Publication of JP2022521840A5 publication Critical patent/JP2022521840A5/ja
Application granted granted Critical
Publication of JP7589168B2 publication Critical patent/JP7589168B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021558810A 2019-04-01 2020-03-30 タンパク質含有製剤を安定化するための組成物および方法 Active JP7589168B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962827402P 2019-04-01 2019-04-01
US62/827,402 2019-04-01
PCT/US2020/025683 WO2020205716A1 (en) 2019-04-01 2020-03-30 Compositions and methods for stabilizing protein-containing formulations

Publications (3)

Publication Number Publication Date
JP2022521840A JP2022521840A (ja) 2022-04-12
JP2022521840A5 true JP2022521840A5 (https=) 2023-04-04
JP7589168B2 JP7589168B2 (ja) 2024-11-25

Family

ID=70480816

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021558810A Active JP7589168B2 (ja) 2019-04-01 2020-03-30 タンパク質含有製剤を安定化するための組成物および方法

Country Status (14)

Country Link
US (1) US20220125928A1 (https=)
EP (1) EP3946457A1 (https=)
JP (1) JP7589168B2 (https=)
KR (1) KR20210145152A (https=)
CN (1) CN113660953A (https=)
AR (1) AR118536A1 (https=)
AU (2) AU2020254582B2 (https=)
BR (1) BR112021019612A2 (https=)
CA (1) CA3133652A1 (https=)
IL (1) IL286811A (https=)
MX (1) MX2021012032A (https=)
SG (1) SG11202110043TA (https=)
TW (1) TWI856084B (https=)
WO (1) WO2020205716A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
US20220193238A1 (en) * 2020-12-17 2022-06-23 Astrazeneca Ab Anti-il5r antibody formulations
WO2023059921A2 (en) * 2021-10-07 2023-04-13 Intelligent Optical Systems, Inc. Enhanced lateral flow assays and devices for detecting analytes in blood samples
CN116478268B (zh) * 2023-05-17 2025-04-25 重庆医科大学附属第三医院(捷尔医院) Bmp2蛋白保护液、bmp2蛋白制剂及其制备方法
CN118294649B (zh) * 2024-04-09 2024-12-13 深圳市迈科龙生物技术有限公司 生物标记物保存液以及生物标记物冻干品的制备方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP2841229B2 (ja) * 1990-04-19 1998-12-24 ライオン株式会社 う蝕ワクチン組成物
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2150803C (en) 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
WO1995019181A1 (en) 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
JP3696267B2 (ja) * 1994-02-28 2005-09-14 天野エンザイム株式会社 生理活性蛋白質の安定化方法
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
PT779806E (pt) 1994-09-09 2001-02-28 Takeda Chemical Industries Ltd Preparacao de libertacao sustentada contendo um sal metalico de um peptido
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
PT831787E (pt) 1995-06-07 2002-02-28 Alkermes Inc Composicao para libertacao sustentada da hormona de crescimento humano
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0941344B1 (en) 1996-11-27 2004-05-19 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-vegf 항체
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥c反応性タンパク質組成物
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
ES2309012T3 (es) 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
AU2002351495A1 (en) 2001-10-17 2003-04-28 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003068821A2 (en) 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
JP4060123B2 (ja) * 2002-05-22 2008-03-12 日本製薬株式会社 タンパク質の失活を抑制する方法
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
CN1802388B (zh) 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
CA2542777C (en) * 2003-10-23 2016-02-02 Chiron Corporation Stabilised compositions
JP4578247B2 (ja) * 2005-01-07 2010-11-10 日本ハム株式会社 蛋白質含有液の保存方法及びそれに使用される希釈液
JP5240970B2 (ja) * 2005-06-08 2013-07-17 キッコーマン株式会社 界面活性剤存在下で安定なコレステロールオキシダーゼ
US7371550B2 (en) * 2005-06-08 2008-05-13 Kikkoman Corporation Cholesterol oxidase stable in the presence of surfactant
PL2135881T3 (pl) 2005-06-20 2012-02-29 Genentech Inc Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2009015345A1 (en) * 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
BR122012024318A2 (pt) * 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
EP2550018B1 (en) * 2010-03-22 2019-02-27 F.Hoffmann-La Roche Ag Compositions and methods useful for stabilizing protein-containing formulations
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program
US20160030349A1 (en) * 2014-08-01 2016-02-04 Boehringer Ingelheim Vetmedica Gmbh Nanoparticles, methods of preparation, and uses thereof
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
EP3615065A1 (en) * 2017-04-28 2020-03-04 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
WO2018201064A1 (en) * 2017-04-28 2018-11-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides

Similar Documents

Publication Publication Date Title
JP2022521840A5 (https=)
TWI653048B (zh) 含有肉毒桿菌毒素的穩定液體組合物
JP4879104B2 (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子ix処方
KR101395064B1 (ko) 보톨리눔 독소의 동결건조제제
JP2024023468A (ja) 安定な融合タンパク質製剤
JP2022526799A5 (https=)
WO2017188356A1 (ja) 抗体含有製剤
CN110234353B (zh) 用于FXIa抗体的新型稳定制剂
JP2019509311A5 (https=)
JP2017514868A5 (https=)
JP2009502972A (ja) タンパク質凝集を抑制する製剤
JP2021532071A5 (https=)
TWI285106B (en) Stable pharmaceutical composition containing factor VIII
JP2017105754A (ja) 低粘度抗体組成物
CN105985942A (zh) 赖氨酰肽链内切酶冻干及贮存保护剂
JP2025517669A (ja) 血漿タンパク質に対する新規な液状剤形物
Wu et al. Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity
WO2000000221A1 (en) Water soluble dry compositions
CN107531747A (zh) 蛋白质的稳定
UA129590C2 (uk) СПОСОБИ ПРОФІЛАКТИЧНОГО ЛІКУВАННЯ РЕКОМБІНАНТНИМ ФВ (рФВ)
WO2016080367A1 (ja) 安定化されたペプチド組成物
JP2000169391A (ja) 安定化された抗トロンビンiii製剤
EP4464724A1 (en) Chimeric protein production process, chimeric protein, gene, immunogenic composition and uses
JP2024513983A (ja) 第viii因子または第viii因子/フォン・ヴィレブランド因子複合体を含む液体組成物
WO2026067668A1 (zh) 抗il-17抗体制剂及其制备方法和应用